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ARTICLE
Genetic Analysis of 103 Candidate Genes for Coronary Artery
Disease and Associated Phenotypes in a Founder Population
Reveals a New Association between Endothelin-1 and High-
Density Lipoprotein Cholesterol
Guillaume Pare´, David Serre, Diane Brisson, Sonia S. Anand, Alexandre Montpetit, Ge´rald Tremblay,
James C. Engert, Thomas J. Hudson, and Daniel Gaudet
Coronary artery disease (CAD) is a major health concern in both developed and developing countries. With a heritability
estimated at ∼50%, there is a strong rationale to better define the genetic contribution to CAD. This project involves
the analysis of 884 individuals from 142 families (with average sibships of 5.7) as well as 558 case and control subjects
from the Saguenay Lac St-Jean region of northeastern Quebec, with the use of 1,536 single-nucleotide polymorphisms
(SNPs) in 103 candidate genes for CAD. By use of clusters of SNPs to generate multiallelic haplotypes at candidate loci
for segregation studies within families, suggestive linkage for high-density lipoprotein (HDL) cholesterol is observed on
chromosome 1p36.22. Furthermore, several associations that remain significant after Bonferroni correction are observed
with lipoprotein-related traits as well as plasma concentrations of adiponectin. Of note, HDL cholesterol levels are
associated with an amino acid substitution (lysine/asparagine) at codon 198 (rs5370) of endothelin-1 (EDN1) in a sex-
specific manner, as well as with a SNP (rs2292318) located 7.7 kb upstream of lecithin cholesterol acyl-transferase (LCAT).
Whereas the other observed associations are described in the current literature, these two are new. Using an independent
validation sample of 806 individuals, we confirm the EDN1 association ( ), whereas the LCAT association wasP ! .005
nonsignificant ( ).Pp .12
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Atherosclerosis is a major health concern in both devel-
oped and developing countries. Although atherosclerosis
can involve almost any artery, its public health burden is
overwhelmingly the result of coronary artery disease
(CAD). In America and most countries of western Europe,
CAD remains the leading cause of death despite dramatic
declines in the CAD mortality rate (American Heart As-
sociation Web site). Moreover, the CAD epidemic is in-
creasingly global, with an estimated 30.9% of all world-
wide deaths attributable to cardiovascular diseases.1
With a heritability estimated at ∼50%,2 there is a strong
rationale to better define the genetic contribution of CAD.
To do so, this project was designed to test 103 candidate
genes in 11,400 individuals from the Saguenay Lac St-Jean
(SLSJ) region of Quebec. This group included both a family
and a case-control sample. We hypothesized that linkage
analysis with the use of haplotypes as multiallelic markers
would result in a powerful method to detect rare, highly
penetrant mutations at these candidate loci. On the other
hand, association analysis would allow us to detect com-
mon polymorphisms with more moderate effects on CAD
and phenotypes of interest.
The SLSJ region is inhabited by an archetypal “founder
effect” population of ∼280,000 individuals, which was
subjected to a first bottleneck with the establishment of
New France by French settlers in the 17th–18th century
and then to a second bottleneck with the founding of the
SLSJ region in the 19th century. Consequently, ∼600 an-
cestors contributed up to 70% of the current genetic pool.3
This could result in decreased allelic and genetic hetero-
geneity, two phenomena that can hinder dissection of the
genetic architecture of complex traits. Thus, the demo-
graphic characteristics of the SLSJ population could offer
advantages in deciphering genetic contributors to CAD.
Material and Methods
Study Sample Description
Three independent samples were collected for this study. All three
samples comprised individuals with proven French Canadian an-
cestry (all four grandparents originated from the SLSJ area). All
individuals with proven or likely mutations in the low-density
lipoprotein (LDL) receptor gene (LDLR [MIM 606945]) and/or li-
poprotein lipase gene (LPL [MIM 609708]) (i.e., those with type
I or type V dyslipidemia) were excluded from analysis. In LDLR,
two deletions (5 kb and 115 kb) and the mutations W66G, E207K,
C646Y, C152W, R329X, C347R, and Y468X were screened. In LPL,
mutations D9N (rs1801177), N291S (rs268), and P207L were
screened. Each individual was extensively phenotyped with a
674 The American Journal of Human Genetics Volume 80 April 2007 www.ajhg.org
Table 1. Classification of Genes
According to Gene Function
Gene Function
No. (%) of Genes
( )np 103
Lipoprotein metabolism 43 (42)
Inflammation 19 (18)
Obesity/diabetes 9 (9)
Hypertension 9 (9)
Coagulation 8 (8)
Miscellaneous 15 (15)
Table 2. Classification of SNPs According
to SNP-Selection Category
Selection Category
No. (%) of SNPs
( )np 1,536
Tagging only 1,325 (86)
Coding only 33 (2)
Literature only 81 (5)
Tagging and coding 37 (2)
Tagging and literature 21 (1)
Coding and literature 21 (1)
Tagging, coding, and literature 18 (1)
clinical history, a pharmacological report, biometric measure-
ments (height, weight, blood pressure, and waist circumference),
and biochemical analysis. Measurements were done after a 3-wk
medication washout (for hypocholesterolemic and antihyperten-
sive drugs). The presence of CAD was ascertained on the basis of
(1) clinical and electrocardiogram criteria or a positive result of
an exercise-tolerance test according to the consensus document
of the joint European Society of Cardiology and the American
College of Cardiology committee4 or (2) evidence of coronary
stenosis of at least 50% in two or more main coronary arteries
from coronary angiography for the investigation of ischemic
heart disease.
Family sample.—Families were ascertained if they had (1) a pro-
band with early CAD (onset at age !55 years for men and age
!65 years for women), (2) at least one first-degree relative with
CAD (not necessarily available for genotyping), and (3) a total of
four or more individuals available for genotyping (either parents
or siblings).
Hospital records were reviewed (especially coronary angiog-
raphy findings) to identify subjects and to confirm the diagnosis.
Coronary angiography findings were available for 92% of pro-
bands, 68% of their affected siblings, and 2% of unaffected sib-
lings. Errors in pedigree assignment were detected using the GRR
software package,5 and mixed-up samples were excluded.
Case-control sample.—The case-control sample comprised indi-
viduals with no familial relationship between each other or with
any of the families used in the family sample. This sample was
ascertained through revisiting of local hospital records (coronary
angiography findings) as well as visits to a local lipid clinic. A
confirmatory coronary angiography (at least two vessels with
150% obstruction) was available for 97% of cases and 69% of
controls.
Validation sample.—To validate new associations, a third sample
was also collected. This sample was recruited through a local lipid
clinic, without awareness of CAD status. Hospital records were
reviewed to confirm the diagnosis. Because angiography is the
cornerstone to both the diagnosis and treatment of CAD, it fol-
lows that a confirmatory angiography was available for 88% of
cases.
The three samples were recruited at the Lipid Clinic and the
Montreal University Community Genomic Medicine Center,
both located at the Chicoutimi Hospital (Quebec). Subjects gave
informed consent to participate in this study and were assigned
a code that systematically denominalized all clinical data.6 This
study received the approval of the Chicoutimi University Hospital
Ethics Committee and the research ethics board at the Montreal
General Hospital.
Biochemical Measurements
Blood samples were obtained after a 12-h overnight fast. Bio-
chemical measurements were performed using standard methods
on a CX7 Beckman automated analyzer. Apolipoprotein B (apoB)
levels were determined using nephelometry. Fasting plasma adi-
ponectin concentrations were measured with a commercial en-
zyme-linked immunosorbent assay (B-Bridge International).
Gene and SNP Selection
A total of 103 candidate genes were selected on the basis of pub-
lished evidence of involvement in CAD risk or suspected bio-
chemical contribution to a disease pathway. A strong emphasis
was put on lipoprotein metabolism genes (table 1). The gene and
SNP panel was specifically designed for the INTERHEART project
(see Web Resources) that is currently underway.7 A total of 1,536
SNPs were genotyped for each individual in the family and case-
control samples. SNP selection was based on linkage disequilib-
rium (LD) data from the International HapMap Project,8 previ-
ously published functional SNPs, and nonsynonymous coding
SNPs. Briefly, SNPs were selected for each gene so as to evaluate
all common SNPs (minor-allele frequency [MAF] 10.05) with a
in each of the HapMap population panels (Yoruba of Iba-2r 1 0.8
dan, Nigeria; U.S. residents with northern and western European
ancestry [CEPH individuals]; and Chinese from Beijing) within
10 kb (both upstream and downstream) of candidate genes. This
was done using the LD-select software,9 which operates by se-
lecting a minimal set of markers such that no allele in the data
set is correlated at an with another one. This process was2r 1 0.8
performed separately for each of the three HapMap panels, and
a final set of markers was derived from the union of all three
population-specific sets. HapMap data release 16 from National
Center for Biotechnology Information build 34 was used. Even
though the samples used in this study are from a European foun-
der population, tagging SNPs from diverse HapMap populations
were genotyped because the INTERHEART project, for which this
panel was designed, is a multiethnic study.
In addition, all known common ( in at least oneMAF 1 0.05
HapMap population) nonsynonymous coding SNPs were in-
cluded. Finally, SNPs with substantial evidence of implication in
CAD or atherosclerosis on the basis of a review of the current
literature were also included. A summary of SNP selection is given
in table 2, and a complete list of selected genes and SNPs is avail-
able online (see the tab-delimited ASCII file, which can be im-
ported into a spreadsheet, of data set 1 [online only]).
Genotyping
The familial and case-control samples were genotyped using the
GoldenGate technology from Illumina. GoldenGate is a propri-
etary technology based on allele-specific primer extension and
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highly multiplex PCR with universal primers, as reviewed by Sy-
vanen.10 A fluorescence polarization assay was established to ge-
notype rs5370 (in EDN1) and rs2292318 (in lecithin cholesterol acyl-
transferase [LCAT]) in the validation sample (see appendix A for
the sequences of primers and probes used).
LD Analysis
LD was analyzed using Haploview.11 Haploview was also used to
make graphical representations of LD (i.e., values). Haplotype2r
blocks were defined according to the definition given by Gabriel
et al.12
Linkage Analysis
Linkage analysis was performed using the MERLIN software pack-
age.13 To account for tight LD between SNPs, they were organized
in clusters, as described by Abecasis and Wigginton14 (see below
for details regarding clusters). Linkage analysis was then per-
formed using these clusters as unlinked markers, thus avoiding
inaccuracies in results caused by violation of the intermarker link-
age-equilibrium assumption. This is especially important since
this effect is more pronounced when parental genotypes are miss-
ing, as was the case for much of our sample.15–17
SNPs with an MAF 10.05 and within 500 kb of each other were
clustered together (under the assumption that SNPs 1500 kb apart
are not in LD and thus would not violate the intermarker linkage-
equilibrium assumption), yielding a total of 99 clusters. However,
since cluster size was limited to 20 SNPs (a computational limi-
tation), three clusters had to be redefined. To keep the maximum
amount of information, no SNP was discarded; instead, these
clusters were broken into smaller parts in such a way as to min-
imize intercluster LD. To accomplish this, two methods were used.
First, clusters were broken according to the haplotype block def-
inition of Gabriel et al.12 and were visualized with Haploview.11
Second, an algorithm was developed to determine the “break
point” that minimizes pairwise between the two newly formed2r
clusters. Both methods yielded similar results. A total of 105 clus-
ters were included in the final analysis.
Dichotomous traits were analyzed for linkage by use of Kong
and Cox linear allele-sharing model LOD scores.18 QTL analysis
was done using a variance-components method13 for age- and
sex-adjusted traits. To gain improved confidence in type I error
estimation and to allow for the fact that genome coverage was
quite heterogeneous (resulting in decreased power and thus ov-
erconservative correction for multiple-hypothesis testing), a gene-
dropping experiment was repeated 1,000 times, and empirical P
values were evaluated. LOD scores were considered significant
when they exceeded a 5% experimentwise type I error cutoff
(here, an experiment is the testing of a single trait at all 105 SNP
clusters).
Association Analysis
Association analysis was performed on the family sample and the
case-control sample separately. Furthermore, a joint analysis
(with both samples combined) was also done. Both additive and
dominant genetic models were tested.
The family-based association test (FBAT) was performed using
QTDT.19 To do so, the identical-by-descent matrix computed using
MERLIN was used to infer major additive effects at each tested
locus, as required by QTDT. The model used included environ-
mental, polygenic, and a major genetic additive effects in its var-
iance assessment. Because FBAT tests for transmission of disease
alleles rather than total association, this analysis is immune to
population stratification. “Total association” was also tested in
the familial sample. The model used included environmental and
polygenic effects in its variance assessment and thus accounted
for the intrafamilial quantitative-trait correlation. To make sure
that positive results were not the result of population stratifica-
tion, the “stratification” option of QTDT was used. As expected
from the stringent criteria for subject selection, no evidence of
stratification was found, thus justifying the use of the “total as-
sociation” option for our analysis.
The case-control and validation samples were analyzed using
standard logistic regression (for CAD status) and anaylsis of var-
iance (for quantitative traits). Analyses were done using R (The
R Project for Statistical Computing Web site), an open-source sta-
tistical package.
Joint analysis of the familial and case-control samples was per-
formed with QTDT by use of the “total association” option. As
for the family sample, the model for the combined samples in-
cluded environmental and polygenic effects in its variance as-
sessment and thus accounted for the intrafamilial quantitative-
trait correlation.
Because variance-components approaches can be sensitive to
deviation from normal distributions and because permutation
testing is not practical for joint analysis, traits were log-trans-
formed when necessary (triglycerides, high-density lipoprotein
[HDL] cholesterol, and adiponectin concentrations), and outliers
were manually removed after inspection of normal quantile-
quantile plots (!10 observations per analyzed trait were removed).
Since there is a possibility that ascertainment for CAD status
might induce false-positive results, all statistically significant as-
sociations were checked for interaction with case-control status.
In other words, analysis was done conditional on the CAD status,
to make sure that effects were the same in cases and controls. No
evidence of interaction was observed, and cases and controls were
thus pooled together for quantitative-trait analysis (data not
shown).
To minimize the number of independent statistical tests per-
formed, the analysis (including linkage analysis) was restricted to
CAD status, waist circumference, HDL cholesterol, LDL choles-
terol, triglycerides, apoB, and adiponectin plasma concentrations.
No environmental exposure was included in our analysis.
Results
Study Samples
A total of 884 individuals from 142 different pedigrees
were included in the family sample (with average sibships
of size 5.7 individuals). A summary of their characteristics
is given in table 3. Only 47 parents were available for
genotyping, and 276 individuals had CAD. As expected,
the case samples were mostly male and had lower levels
of HDL cholesterol and lower levels of adiponectin than
did the control samples. Unexpectedly, case samples had
lower arterial pressure compared with that of control sam-
ples. This may be explained by a stronger adherence to
antihypertensive medication among case patients than
among controls. Moreover, case patients are expected to
receive more aggressive treatment than are unaffected
family members. Finally, changes in lifestyle following a
cardiovascular event may also explain this observation.
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A total of 558 individuals were included in the case-
control sample. As expected, the case samples were mostly
male and had lower levels of HDL cholesterol, lower levels
of adiponectin, and higher waist circumference than did
the control samples (table 3). Unexpectedly, case samples
had lower levels of triglyceride compared with levels in
controls. This may reflect the fact that control subjects
were recruited through a lipid clinic. Alternatively, it may
result from changes in lifestyle following a cardiovascular
event, as well as an unwillingness to discontinue medi-
cation for the purposes of the study.
A total of 806 individuals were included in the valida-
tion sample. As expected, the case samples were mostly
male and had lower levels of HDL cholesterol, higher lev-
els of triglyceride, lower levels of adiponectin, and higher
waist circumference than did control samples. As shown
in table 3, case subjects also had, on average, lower blood
pressure than that of control subjects.
Genotyping
Of 1,536 SNPs genotyped in the familial and case-control
samples, 1,481 passed quality-control requirements (55
SNPs failed). Furthermore, our analyses were restricted to
SNPs with an MAF 10.05, for a total of 1,179 SNPs. Because
some of these SNPs are in perfect LD in our sample, a
further 200 SNPs were excluded from analysis. Thus, 979
SNPs were used for the final analysis. Since the panel used
was designed to capture common and meaningful genetic
variation in diverse populations derived from Asia, Africa,
and Europe, it is not unexpected that several minimally
or noninformative SNPs will be observed when this panel
is used in a single founder population. Using only the
CEPH individuals for tagging, we would have included
only 879 of the 979 SNPs to capture all information with
. The additional 100 SNPs are informative in the2r 1 0.8
Asian and African populations for tagging of haplotypes
but are redundant in Europeans (i.e., the LD between two
SNPs is 10.8 in Europeans and !0.8 in Africans and/or
Asians). These 100 SNPs are common in Europeans
( ) but are in LD ( ) with a SNP already2MAF 1 5% 0.8 ! r ! 1
included in the genotyping panel. Overall, the call rate
for the 979 SNPs used in the analyses was 199%. No sig-
nificant deviation from Hardy-Weinberg equilibrium was
observed.
Linkage
A single SNP cluster was deemed to be suggestive of linkage
according to the Lander and Kruglyak definition.20 This
result was for an HDL cholesterol QTL at the MTHFR/
NPPA/NPPB SNP cluster, which had a LOD score of 2.52
and a corresponding P value of .0003. The HDL cholesterol
linkage peak at the MTHFR/NPPA/NPPB locus remained
statistically significant after the gene-dropping experi-
ment ( ). No other significant peak was observed.P ! .05
Complete linkage results are available online (see the tab-
delimited ASCII file, which can be imported into a spread-
sheet, of data set 2 [online only]).
Association
Testing all SNPs for association with a trait generates a
considerable number of tests. To account for multiple-
hypothesis testing, a conservative Bonferroni correction
was applied, with P values (.05/979) deemed5 5.0# 10
to be significant. Use of such a threshold results in a type
I error of 5% per trait analyzed. Briefly, a total of 12 sig-
nificant associations were found using the more powerful
joint analysis (summarized in table 4). The SNPs at rs5370
(in EDN1), rs3764261 (in CETP), and rs2292318 (in LCAT)
were associated with HDL cholesterol levels. The SNPs at
rs619054, rs651821, rs662799, and rs5128 (all part of the
APOC3/APOA4/APOA5 cluster) were associated with tri-
glyceride levels. Whereas the SNP at rs7412 (in APOE) was
associated with both LDL cholesterol levels and apoB lev-
els, the SNPs at rs405509 and rs429358 (also in the APOE
locus) were associated only with apoB levels. Finally, the
SNP at rs266729 (in the ADIPOQ locus) was associated with
adiponectin concentrations. No SNP passed the Bonfer-
roni cutoff in either the case-control or the family sample
without also being significant in the joint analysis.
Because the associations between HDL cholesterol and
rs5370 (in EDN1) and rs2292318 (in LCAT) are new, these
two SNPs were genotyped in an independent validation
sample. Whereas the association with rs2292318 was not
statistically significant (one-sided ), the associationPp .12
with rs5370 was replicated with statistical signficance,
with a one-sided P equal to .004. Furthermore, this latter
association was found to be sex dependent, with a much
stronger association in women (two-sided Pp 1.3#
for the joint analysis; one-sided for the val-510 Pp .007
idation sample) than in men (two-sided for thePp .14
joint analysis; one-sided for the validation sam-Pp .07
ple). The call rate for rs5370 in the validation sample was
98.8%, and the call rate for rs2292318 was 99.2%. Both
SNPs were in Hardy-Weinberg equilibrium. An overview
of the association analysis is given in figure 1.
Discussion
Although several associations have been observed in this
study, one of the most striking aspects of this report is the
lack of association (or linkage) with CAD status, the pri-
mary phenotypic outcome that motivated this study. This
is probably a consequence of the tremendous complexity
of the trait. Indeed, positive CAD status was defined clin-
ically in the current study, with overlapping but different
diagnostic categories combined together (i.e., angina and
myocardial infarction). Thus, there is the possibility that
different genetic polymorphisms are involved in these en-
tities, with resulting decreased power to detect them. In
addition, even “control” individuals may have athero-
sclerosis, a fact that might have been compounded by the
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Table 4. Summary of Statistically Significant Associations
Trait, Gene,
and SNP
SNP Classification
MAF
P Value for
Coding Tagging
Literature
Based Joint Analysisa
Total Association in
Family Sampleb
QTDT in Family
Samplec
Case-Control
Sampled
HDL cholesterole:
EDN1:
rs5370    .21 51# 10 .00820 .00860 .00300
CETP:
rs3764261    .28 69# 10 .01820 .06990 .00002
LCAT:
rs2292318    .12 52# 10 .00130 .00250 .00570
LDL cholesterol:
APOE:
rs7412    .15 62# 10 !.00001 .00200 .11270
Triglyceridese:
APOA5:
rs619054    .25 55# 10 .01460 .09940 .00210
rs651821    .10 85# 10 .00520 .14170 !.00001
rs662799    .10 84# 10 .00410 .15900 !.00001
APOC3:
rs5128    .11 63# 10 .00830 .29490 .00005
apoB:
APOE:
rs7412    .15 123# 10 !.00001 .00001 .00030
rs405509    .48 62# 10 .00002 .00020 .01880
rs429358    .15 63# 10 .00006 .00004 .01490
Adiponectine:
ADIPOQ:
rs266729    .30 55# 10 .00007 .00040 .08230
a Joint analysis refers to the analysis of the family and case-control samples combined.
b Total Association in Family Sample refers to the analysis of the family sample with the “total association” option of QTDT.
c QTDT in Family Sample refers to the analysis of the family sample with a transmission-based test (the QTDT).
d Case-Control Sample refers to the analysis of the case-control sample by use of linear regression.
e HDL cholesterol values, triglyceride levels, and adiponectin blood concentrations were log-transformed before analysis.
recruitment of controls from a lipid clinic and a hospital.
Finally, our sample size may be too small to detect some
associations, especially if these associations involve mod-
est effects discovered through very large samples. In the
case of the linkage analysis, only 86 of the 142 families
proved to be informative for CAD status, thereby reducing
our power. Furthermore, effects reported in the literature
may be inflated by the “regression toward the mean” ef-
fect, and, in fact, many published findings may be false-
positive results.21 In this context, it is not surprising that
the analysis of intermediate phenotypes yielded more re-
sults, presumably because effects of functional SNPs are
more directly measured. Moreover, a recent study7 has
shown that nine easily measured and potentially modi-
fiable risk factors (besides age and sex) account for 190%
of the population-attributable risk of an initial acute my-
ocardial infarction. It follows that the most important sus-
ceptibility genes with regard to CAD risk are likely to affect
or interact with one of these risk factors (and related in-
termediate phenotypes).
The HDL cholesterol QTL peak at the MTHFR/NPPA/
NPPB locus (chromosome 1p36.22) is quite interesting. A
single linkage study in the literature gave some evidence
of an HDL cholesterol QTL on chromosome 1p36 (LOD
1.8).22 Whereas there is scant literature to support involve-
ment of either natriuretic peptide precursor A or B (NPPA
or NPPB) in determining HDL cholesterol levels, some evi-
dence hints that methylenetetrahydrofolate reductase
(MTHFR) itself is implicated.23 Many other interesting can-
didates are in the 1p36 genomic area, including a cluster
of phospholipase A2 genes and a retinol binding protein
gene (RBP7).
Given the role of rare, highly penetrant mutations in
the causation of the traits under study (e.g., see the work
of Pajukanta24), it might seem surprising not to have found
more linkage peaks. Moreover, the fact that SNP clusters
were located on candidate genes would have been ex-
pected to result in increased power, since maximum link-
age information was available for these genes. Several
non–mutually exclusive explanations can explain these
results. First, it may be that no highly penetrant mutations
are present in the genes that were tested in these families.
Second, the heterogeneous distribution of our clusters on
the genome precludes an efficient use of multipoint link-
age analysis. Third, the fact that tagging SNPs were chosen
to capture common variation over relatively small loci
makes some SNP clusters not informative enough for the
purpose of tracking the segregation of chromosomes in
these families. For example, some clusters are character-
ized by a single haplotype with a frequency 10.75, ren-
dering many families uninformative.
Contrary to the linkage analysis of the families, many
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Figure 1. Overview of the association analysis. The family and
case-control samples were combined to perform an association
analysis (i.e., the joint analysis). Twelve associations proved to
be statistically significant. Of these, 10 are either known in the
literature or in LD with known functional SNPs. The two remaining
associations are new and thus were tested in the validation sample.
The association between rs5370 and HDL cholesterol concentra-
tions was confirmed in the validation sample.
traits demonstrated significant evidence of association in
the joint analysis of the family and case-control samples.
This is not surprising, because association methods are
recognized to be a more powerful tool for detecting com-
mon variants that have a lower effect on genetic risk.25
Furthermore, the genotyping panel was designed to detect
such common variants. Of the 12 different SNPs with pos-
itive associations found, 10 either are already described in
the literature or are in LD with known functional SNPs.
Our 12 significant associations stand out with regard to
the level of significance achieved. The use of a less con-
servative correction for multiple testing (such as false-dis-
covery rate) did not result in any additional significant
associations (data not shown). We ruled out the possibility
that the associations observed were an artifact due to sam-
ple heterogeneity, since we observed very similar effects
when cases and controls were analyzed separately (see
“Material and Methods” section for details). Because the
associations between HDL cholesterol and the SNPs rs5370
and rs2292318 are new, these are the main focus of our
discussion.
Epidemiological studies consistently show low HDL
cholesterol to be an independent risk factor for CAD.26 In
fact, HDL cholesterol has been shown to be the most
highly predictive risk factor for CAD in prospective stud-
ies.27,28 LCAT catalyzes the transfer of a fatty acyl residue
from phosphatidyl-choline to cholesterol, resulting in ly-
sophosphatidylcholine and cholesteryl ester.29 LCAT cat-
alyzes synthesis of the major portion of cholesteryl esters
in human plasma, and, since it is mainly activated by
apoA1 (the principal apolipoprotein of HDL), its activity
is paramount to HDL cholesterol determination as well as
HDL-mediated transport of cholesterol from peripheral tis-
sues to the liver.30 Marked HDL deficiency and modestly
elevated triglycerides characterize (among other pheno-
types) LCAT-deficient patients (i.e., those with fish-eye dis-
ease [MIM 136120]).31 No common functional polymor-
phism at the LCAT locus has yet been definitively
associated with HDL cholesterol. Two studies suggested a
role of another LCAT SNP in HDL cholesterol,32,33 but their
conclusions relied on small sample sizes (3 and 26 het-
erozygotes). The discovery in our study of a significant
association between rs2292318 and HDL cholesterol thus
represents a novel finding, with the minor allele associated
with higher HDL cholesterol values under an additive
model (each minor allele increases HDL cholesterol by
7.6%). Because rs2292318 could be in LD with a rarer,
highly penetrant mutation, care was taken to ensure that
a few outliers did not drive the association (which was
not the case; see fig. 2). This SNP is located 7,691 bp up-
stream of the transcription start site of LCAT and is in-
tronic to SLC12A4, a gene encoding an electroneutral
potassium-chloride cotransporter whose exact function
remains unknown. As demonstrated by LD analysis,
rs2292318 does not seem to be part of a haplotype block
encompassing the LCAT coding region. Compatible with
the hypothesis that rs2292318 is (or is in LD with) a LCAT
regulatory SNP, it has association not only with HDL cho-
lesterol concentration but also with triglyceride concen-
tration, although this last association is weaker (Pp
). The fact that the minor allele is the “protective”.0031
allele (with regards to CAD) can be explained by yet-to-
be-discovered pleiotropic effects of LCAT or by past selec-
tion for low HDL cholesterol levels.
rs2292318 did not show a statistically significant asso-
ciation with HDL in the validation sample (one-sided
). Despite failing to reach statistical significance,Pp .12
individuals with the minor allele at rs2292318 had higher
levels of HDL (mean 1.22 mmol/liter) than did individuals
with the major allele (mean 1.17 mmol/liter), which is
consistent with the direction of the original association
we identified. Two hypotheses can explain this result.
First, the association observed may be a false-positive re-
sult. Second, because of its smaller sample size and re-
gression to the mean, our validation sample may be un-
derpowered to replicate a true-positive association, a
hypothesis consistent with the nonsignificant trend that
was seen. The power is estimated at 80% on the basis of
the sample size of the validation sample and the effect
size measured in the original association study. Further
genetic and functional studies are required to confirm our
680 The American Journal of Human Genetics Volume 80 April 2007 www.ajhg.org
Figure 2. Association between HDL cholesterol concentrations
and rs2292318 (in LCAT). Age- and sex-adjusted, log-transformed
HDL cholesterol concentrations are shown as a function of
rs2292318 genotype (for family and case-control samples com-
bined). A box-and-whisker plot is used; by graphically displaying
the median and the end of the 1st and 3rd quartiles, these plots
provide a robust assessment of the associations observed. Overall,
1,106 G/G, 307 A/G, and 19 A/A individuals are represented
( ).Pp .00002
Figure 3. Association between the HDL cholesterol concentra-
tions and rs5370 (in EDN1). Age- and sex-adjusted, log-trans-
formed HDL cholesterol concentrations are shown as a function of
rs5370 genotype with both sexes combined (“Total”). Overall, 894
G/G, 474 T/G, and 64 T/T individuals are represented using a box-
and-whisker plot ( ). Data are also shown for both sexesPp .00001
separately—525 G/G, 256 T/G, and 28 T/T males are represented
( ), and 369 G/G, 218 T/G, and 36 T/T females are repre-Pp .14
sented ( ). All three box-and-whisker plots were madePp .00001
by combining the family and case-control samples. By graphically
displaying the median and the end of the 1st and 3rd quartiles,
these plots provide a robust assessment of the associations observed.
association result and to characterize the relationship be-
tween rs2292318 and the regulation of LCAT or SLC12A4.
EDN1 is a 212-aa protein secreted by endothelial cells
of the vasculature as a 21-aa peptide.34 It has been dem-
onstrated to possess potent vasoconstrictor activity, as well
as metabolic properties. Because of the vasoconstrictor ac-
tivity of EDN1, genetic studies of EDN1 have been mainly
focused on blood pressure. Indeed, an amino acid substi-
tution (Lys/Asn) at codon 198 (rs5370) in EDN1 has been
associated with high blood pressure. This association is
not straightforward and seems to hold true only in over-
weight individuals.35–37 Even more puzzling is the fact that
this nonsynonymous substitution occurs at codon 198, in
a part of the protein that is cleaved by various proteases
and whose function remains unknown.38 Interestingly,
when tested for association with diastolic blood pressure
in our sample, rs5370 did show statistically significant
( ) evidence of interaction with waist circumfer-Pp .01
ence, as observed in the literature. However, the most
striking association involving rs5370 in our study is with
HDL cholesterol ( ) (fig. 3), with the minor5Pp 1.0# 10
allele T (Asn) associated with lower HDL cholesterol values
(the association remains significant when tested using a
nonparametric method, Kendall’s rank correlation; Pp
). In view of the fact that this is a newly described.0007
association, we sought to confirm it, using data from the
literature. A single study of hypertension tested rs5370 for
association with HDL cholesterol.36 Although HDL cho-
lesterol was listed among the lipoprotein-related pheno-
types, those authors did not observe a statistically signif-
icant relationship with HDL. Given that their sample
consisted mainly of men (85.3%), we tested whether the
effect of rs5370 was sex specific in our sample. Indeed, we
observed a marked sex interaction (fig. 3), with women
showing a strong association between rs5370 and HDL
cholesterol ( ), whereas, in men, no such sig-5Pp 1.3# 10
nificant association was identified ( ).Pp .14
Recent evidence suggests that endothelin could have an
active role in metabolism in general and insulin resistance
in particular. EDN1 inhibits IRS-1, an important mediator
of insulin action, in smooth muscle cells39 and decreases
insulin-stimulated translocation of GLUT4, a glucose
transporter, in adipocytes.40,41 Of particular interest, one
report42 showed that endothelin could modulate the se-
cretion of adiponectin by adipocytes in vitro. We thus
tested whether rs5370 had an effect on adiponectin con-
centrations, and, indeed, we found a statistically signifi-
cant association ( overall; for women;Pp .006 Pp .0004
for men). This effect was nevertheless not suffi-Pp .80
cient to explain the association with HDL cholesterol,
since correction of HDL cholesterol for adiponectin re-
sulted in a weakened but still significant association.
Genotyping of rs5370 in our validation sample con-
firmed the observed association (one-sided ;Pp .004
for the nonparametric Kendall’s rank correlationPp .005
test) (table 5). We note that the power to replicate this
association in the validation cohort was excellent (90%),
notwithstanding the effect of regression toward the mean.
Interestingly, the effect of rs5370 is also sex dependent in
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Table 5. Means (SD) of Log-Transformed, Sex- and Age-
Adjusted HDL Cholesterol Concentrations, by rs5370
(EDN1) Genotype
rs5370
Genotype
Family Samplea
Case-Control
Samplea
Validation
Sampleb
HDL n HDL n HDL n
G/G .0556 (.28) 553 .0262 (.30) 341 .017 (.33) 583
T/G .0092 (.32) 229 .0791 (.27) 181 .031 (.35) 199
T/T .0018 (.26) 29 .1621 (.35) 35 .159 (.35) 20
a Negative values for the case-control sample and positive values for
the family sample stem from the fact that the samples were pooled
together before adjustment for age and sex (to improve the accuracy of
the regression).
b The validation sample was adjusted for age and sex on its own, to
maintain independence.
the validation sample. Whereas a weak association is seen
in males (one-sided ), a much more pronouncedPp .07
association is observed in females (one-sided ).Pp .007
Combining all three samples, each minor allele decreases
HDL cholesterol by 5.5% (3.3% in men and 8.7% in
women). Overall, rs5370 explains 1.0% of the total vari-
ance in HDL cholesterol levels (0.3% in men and 2.5% in
women). Furthermore, each minor allele is associated with
a 12.6% higher risk of CAD (one-sided ), which isPp .06
near but slightly higher than what would be expected
from its effect on HDL cholesterol. Using these numbers,
the population attributable risk of rs5370 in our samples
is estimated to be 4.8%.
In conclusion, the possibility that EDN1 plays a direct
role in HDL metabolism is quite exciting, because it would
provide a link between endothelial dysfunction and lipo-
protein metabolism. In fact, this could be the first evidence
of endothelial cells having a direct regulatory role on li-
poprotein metabolism. Compatible with this hypothesis,
an epidemiological study of patients who underwent renal
transplant found that the trait most strongly correlated to
plasma EDN1 concentration is HDL cholesterol.43 The pre-
sent study has shown a genetic link between endothelial
function and lipid metabolism, providing the basis for
physiological studies of this interaction.
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Appendix A
Table A1. Fluorescence Polarization Probes and
Primers Used to Genotype rs5370 and rs2292318
SNP and Primer or Probe
Primer Sequence
(5′r3′)
rs5370:
PCR primer forward TCTTGCTTTATTAGGTCGGAGACC
PCR primer reverse TTTGAACGAGGACGCTGGTC
Probe sense ATGATCCCAAGCTGAAAGGCAA
Probe antisense CACATAACGCTCTCTGGAGGG
rs2292318:
PCR primer forward CCTTTATGGATCCTGTGGGAACATCCCCAG
PCR primer reverse CCCAACCTTACGACCGACTC
Probe sense CTGTGGGCTCAAGAGCAAGA
Probe antisense GGTCCTCCCTCCCGTC
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American Heart Association, http://www.americanheart.org/
INTERHEART, http://www.ccc.mcmaster.ca/interheart/index.htm
International HapMap Project, http://www.hapmap.org/index
.html.en
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for LDLR, LPL, and fish-eye disease)
The R Project for Statistical Computing, http://www.r-project.org
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